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Hashimoto Encephalopathy in Children
Sir, Hashimoto encephalopathy (HE) is a rare but controversial entity encompassing a variety of neuropsychological presentations in the setting of autoimmune thyroid disease. The lack of clarity in the nomenclature and pathophysiology as well as absence of uniform diagnostic criteria make the diagnosis more challenging. We add a new case of HE in an adolescent girl and review pediatric HE.
A 14-year-old previously healthy girl was admitted with 1 day history of vomiting and encephalopathy. She had three episodes of non-projectile vomiting and received over-the-counter antiemetic. Subsequently, parents noticed involuntary urination, unresponsiveness to verbal commands, irritability, and then drowsiness. On admission to the hospital, her Glasgow Coma Scale score was 8. She was maintaining vitals and was hemodynamically stable. There were no meningeal signs or focal deficit. Eye examination, tone, and brainstem, superficial and deep tendon reflexes were normal. Child was admitted to the intensive care unit and was started on antimicrobials for presumed infectious etiology. She had one brief seizure. Initial blood work including blood counts, renal and liver function tests, C-reactive protein, erythrocyte sedimentation rate, serum ammonia, blood gas analysis, and vitamin B12 levels were normal, except high value of serum lactate (33.9 mg/dl, range: 4.5-14.4 mg/dl). Magnetic resonance imaging (MRI) of the brain and cerebrospinal fluid (CSF) examination were normal. Electroencephalography (EEG) showed generalized slowing of the background activity (delta range activity) without any epileptiform discharges. Patient had deterioration of sensorium on Day 2 of hospital stay and was electively intubated and ventilated. Further investigations including urine toxicology screen, CSF and serum profile for autoimmune encephalitis, antinuclear antibodies, and urine for porphobilinogen were normal. Thyroid profile was found abnormal with decreased thyroid-stimulating hormone (TSH) (0.025 micU/ml; range: 0.700-6.400 micU/ml), decreased free T3 (1.81 pg/ml; range: 2.90-5.10 pg/ml), and normal free T4 (2.27 ng/dl; range: 0.80-2.30 ng/dl). Patient was started on intravenous immunoglobulin (IVIG) (2 g/kg), levothyroxine, and injectable thiamine, with no improvement. Testing revealed high levels of anti-thyroperoxidase (TPO) antibodies (79.8 IU/ml, normal: <60 IU/ml) and anti-thyroglobulin (Tg) antibodies (74.7 IU/ml; normal: <60 IU/ml). A diagnosis of HE was made and pulse IV methylprednisolone (1 g/day) was started. There was a dramatic response to steroid therapy with return to normal sensorium within 3 days. Patient was discharged home after 7 days on oral steroids and levothyroxine. On 2.5 months of follow up, the patient is asymptomatic, off steroids, and her thyroid profile is normal.
We reviewed the literature for pediatric patients with HE. Forty-seven articles detailing 74 pediatric patients and the present patient were included. Average age of presentation is 13.1 years (range: 2 years 10 months-18 years) and a majority are female (F:M = 5:1). Duration of symptoms before diagnosis ranges from few days to 9 years. Around 20% present with acute onset. The most common clinical features are seizures (69%, status epilepticus: 25%, refractory epilepsy: 3%), alteration in sensorium (60%), psychosis (37%), behavioral alterations (33%), headache (25%), and cognitive decline (21%). Other presenting symptoms are academic issues, sleep disturbances, movement disorders, mood changes, and emotional liability. Recurrent strokes, myoclonus, ataxia, and tremors are less common compared to adults. [1] A number of pathogenetic mechanisms have been suggested. Female prevalence, presence of autoantibodies, fluctuating course, and response to immunomodulatory therapy suggest the autoimmune nature of the disease. A shared target antigen between thyroid gland and central nervous system, [2] neurotoxic effects of thyroid hormones, and interference of neurotransmission by antibodies are suggested mechanisms. [3] Other autoantibodies have been found in a few patients. [4] However, antithyroid antibodies are also found in hypothyroid patients and normal adult population. It is conceivable that these antibodies are the markers for a specific neurologically targeted autoimmunity in these patients. Vasculitic process, [5] primary demyelination, [2] or an immune complex-mediated process have also been proposed. It is possible that some patients with presumed HE have a second autoimmune mechanism. [6] The thyroid status in patients with HE is variable. Around 17% children were found to have pre-existing hypothyroidism. At the time of diagnosis, 47% children are euthyroid, 50% are hypothyroid, and 3% are hyperthyroid. Anti-TPO antibodies are elevated in 97% patients and anti-Tg antibodies are raised in 81% patients. Antithyroid antibody titers do not correlate with the severity and presentation of the disease [7] and may even be undetectable at disease onset. [3] EEG is found to be abnormal in around 86% patients. The most common abnormality is generalized slowing of the background activity seen in around half the patients. Other abnormalities included focal slowing, focal or generalized epileptiform activity, and rarely electrical status epilepticus and burst suppression pattern. EEG acts as a marker of encephalopathy and serial EEGs may reflect clinical improvement. [8] CSF analysis is normal in nearly half the patients. Increased CSF protein levels are found in another 48% and pleocytosis in 4%. Increased cellular count is mild. CSF antibodies were found elevated in half the tested patients (n = 6); all these patients also had positive serum antibodies. Computerized tomography (CT) of the brain has poor yield. A higher proportion of pediatric MRIs are found to be normal (67%) as compared to adults. [9] The most common abnormality is non-specific white matter changes. Multiple other abnormalities have been reported.
Patients with HE, respond to immunotherapy. Some patients respond to levothyroxine alone. Around 30% patients received only steroids and 36% received a combination of steroids and levothyroxine. Since there are no controlled trials, the optimum duration and dose of steroid therapy is unclear. Many studies use high-dose IV methylprednisolone followed by tapering doses of prednisolone. [9] There is incomplete response to steroids in around one-fourth patients who warrant second-line immunosuppression. Such patients have been described in case reports and small case series. IVIG has been used in 13 patients with no benefit in 8 and good response in 5 patients. Plasma exchange and rituximab have been reported to be beneficial. Methotrexate, cyclophosphamide, and azathioprine have been tried in varying combinations and duration. Response to flunarizine and risperidone has been reported. [1, [8] [9] [10] [11] A total of 26 relapses were reported in 15 patients (time range: 14-518 days). Around 20% pediatric patients are likely to be left with sequelae. The likelihood of residual deficits did not correlate with the duration and severity of symptoms.
HE encompasses a huge array of neurological and psychiatric symptoms tied together by raised titers of antithyroid antibodies and response to immunotherapy. It is likely underdiagnosed in children. The availability of disease-modifying treatment makes the diagnosis imperative.
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There are no conflicts of interest. An 18-month-old girl presented with concerns of language delay and recurrent seizures from the age of 12 months. She was the second born to a nonconsanguineous couple and had an uneventful perinatal period. Her development was age-appropriate except in the language domain. She recognized words for common items like "cup," and listened when spoken to, but her expressive language was restricted to gurgling sounds and babbling. Her seizures were brief, generalized tonic, and were associated with a short period of postictal drowsiness. Grinding of teeth was also noted. The seizure frequency had gradually increased to 4-5 episodes per week over the last 6 months, and the parents had noticed the appearance of generalized tremulousness and lack of any new milestones. At 18 months of age, she was able to take a few steps by holding on to furniture, pick up small objects, and wave bye-bye. Her speech was unclear, she used gestures to communicate and was still babbling.
On examination, she was easily excitable and had frequent unprovoked episodes of laughter. Her mouth was constantly open, and she had a protruded tongue. She also exhibited abnormal, involuntary, brief, non-stereotypic uncoordinated, jerky movements of arms and legs. Her occipitofrontal head circumference was 42.5 cm suggestive of microcephaly (−3.05 Z score by WHO growth charts). Her neurological examination revealed mild generalized hypotonia. Her magnetic resonance imaging of the brain was unremarkable [ Figure 1 ]. Her electroencephalography (EEG) at 1 year of age showed runs of high amplitude generalized irregular delta waves with multifocal epileptiform discharges suggestive of hypsarrhythmia [ Figure 2 ]. A repeat EEG at 18 months of age showed rhythmic delta activity more pronounced in the frontal region with superimposed notched appearance on the descending phase of slow wave [ Figure 3 ]. Her karyotype was normal (46, XX). Fluorescence in situ hybridization confirmed the diagnosis of Angelman syndrome (AS) by microdeletion of 15q11-q13 in all 100 cells using Vysis Prader-Willi/Angelman region DNA probe LS1 small nuclear ribonucleoprotein polypeptide N. A neurorehabilitative program was initiated, and antiepileptic drug titration was done to control epilepsy.
dIscussIon
AS is a rare neurogenetic disorder with a prevalence of 1:10000-1:40000. [1] The consistent clinical picture comprises of severe intellectual impairment, easily excited behavior phenotype with frequent laughters, balance, and speech impairment. [2] Fascination with water and prominent microbrachycephaly with protruded tongue are clinical hints. One of the problems for the early diagnosis is that the complete phenotypic expression becomes evident only after 3 to 4 years. Epilepsy in AS typically develops at 1-3 years of age with onset ranging from 1 month to 20 years. Most frequent seizure types are atypical absence, generalized tonic-clonic, and myoclonic seizures. [3] Vendrame et al., in their prospective study of 115 children with AS, identified age as robust predictor of seizure onset, with the odds of developing seizures increasing by a factor of 1.29 for every year of life. [4] The electroencephalographic patterns, although are not pathognomonic, are sufficiently characteristic for the diagnosis. Excessive hypersynchronous electrical activity over the thalamocortical and hippocampal networks secondary to misregulation of gamma-aminobutyric acid inhibitory system is the proposed mechanism of epilepsy in AS. [5] The typical EEG patterns are, in general, detected early in the course of syndrome, even before the onset of epilepsy. Another interesting facet is the lack of difference in EEG findings in patients with and without epileptic seizures.
Boyd et al. first described three unequivocal patterns of electrophysiological activity in AS as follows: (a) prolonged rhythmic theta 4-6 s theta activity more evident in the centrotemporal region; (b) generalized rhythmic 2-3 s delta
